Právní předpis byl sestaven k datu 19.12.2013.
Zobrazené znění právního předpisu je účinné od 25.12.2012 do 19.12.2013.
97
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Xx. x. x., x. 46/2008 Xx. x. x. a x. 47/2012 Sb. m. x. x Xxxxxxxxxxx xxxxxx proti dopingu xx xxxxxx
Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, že xxx 16. listopadu 2011 xxxx xxxxxxxxx ředitelkou XXXXXX oznámeno schválení xxxxxx znění Přílohy X - Xxxxxxx xxxxxxxxxx xxxxx a xxxxx - Mezinárodní xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx dopingu ve xxxxxx.1)
X xxxxx xxxxxx Přílohy X xxxxxxxx souhlas Parlament Xxxxx xxxxxxxxx.
Nové xxxxx Přílohy I xxxxxxxxx v xxxxxxxx x souladu s xxxxxxx 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2012 x xxxxx dnem xxxxxxxxx x platnost x xxx Xxxxxx xxxxxxxxx. Xxxx vstupu xxxxxx xxxxx Přílohy X x platnost xxxxxxxx platit xxxxx Xxxxxxx I Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx platné xx 1. xxxxx 2011 x xxxxxxxxx xxx č. 47/2012 Sb. m. s.
Anglické xxxxx Přílohy I x xxxx xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
1) Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx přijatá xxx 19. října 2005 v Paříži xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s.
XXXXXXXXXXX XXXXXX XXXXX DOPINGU XX XXXXXX
Xxxxxxx X - Xxxxxx xxxxxxxxxx látek x xxxxx - Xxxxxxxxxxx xxxxxxxx
Xxxxx, 1. xxxxx 2012
XXXXXX XXXXXXXXXX XXXXX A XXXXX XXXXXXX PRO XXX 2012
SVĚTOVÝ XXXXXXXXXXXXX KODEX
Xxxxxx xx 1. xxxxx 2012
Xxxxx článku 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx všechny Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx xxxxx ze xxxxxx X1, X2, X4.4, X4.5 x X6(x) x Xxxxxxxxxx xxxxx X1, X2 x X3.
LÁTKY X XXXXXX XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX XXXXXX) |
XXXXXXXX LÁTKY
X0. XXXXXXXXXXX XXXXX
Jakákoliv xxxxxxxxxxxxx xxxxx, která xxxx xxxxxxxx v xxxxxxxxxxxxx sekcích Xxxxxxx x není xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx zdravotnickým xxxxxxxxxx xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx výzkumu xxxx xx ukončené xxxxxxxxxx, syntetické xxxxx, xxxxxxxxxxx léky), xx xxxxxxxx stále.
X1. XXXXXXXXXX XXXXX
Xxxxxxxxxx xxxxx xxxx xxxxxxxx.
1. ANDROGENNÍ XXXXXXXXXX XXXXXXXX (XXX):
(x) Xxxxxxxx* AAS, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-androst-1-en-3β,17β-diol); 1-androstendion (5α-xxxxxxx-1-xx-3,17-xxxx); bolandiol (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17β-hydroxy-17α-methyl-5α-androstano[2,3-c]-furazan); gestrinon; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; mesterolon; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); metenolon; xxxxxxxxxxx; metasteron (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); methyldienolon (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); methyltestosteron; metribolon (xxxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9,11-trien-3-on); xxxxxxxxx; xxxxxxxxx; 19-norandrostendion (estr-4-en-3,17-dion); xxxxxxxxxx; norethandrolon; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; prostanozol (17β-hydroxy-5α-androstano [3,2-x]xxxxxxx); quinbolon; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-homo-pregna-4,9,11-trien-17β-ol-3-on); xxxxxxxxx x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.
(b) Xxxxxxxxx** XXX, xxxxx xxxx xxxxxx exogenně:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX), xxxxxxxxxxx x xxxxxx xxxxxxxxxx x isomery, xxx xx s omezením xxxxx na xx:
5α-xxxxxxxxx-3α,17α-xxxx | 5-androstendion (androst-5-en-3,17-dion) |
5α-xxxxxxxxx-3α,17β-xxxx | |
5α-xxxxxxxxx-3β,17α-xxxx | xxx-xxxxxxxxxxxxxxxxxx |
5α-androstan-3β,17β-diol | epitestosteron |
xxxxxxx-4-xx-3α,17α-xxxx | 3α-xxxxxxx-5αxxxxxxxxx-17-xx |
xxxxxxx-4-xx-3α,17β-xxxx | 3β-xxxxxxx-5αxxxxxxxxx-17-xx |
xxxxxxx-5-xx-3β,17α-xxxx | 7α-xxxxxxx-XXXX |
xxxxxxx-5-xx-3α,17α-xxxx | 7β-hydroxy-DHEA |
xxxxxxx-5-xx-3α,17β-xxxX | 7-xxxx-XXXX |
androst-5-en-3β,17α-diol | 19-xxxxxxxxxxxxxx |
4-xxxxxxxxxxxxx (androst-4-en-3β,17β-diol) | 19-xxxxxxxxxxxxxxxxx |
2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx androgenových xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
Xxx xxxxx xxxxxxx xxxx xxxxx: * "xxxxxxxx" xx xxxxxxxx x látce, xxxxxx xxxx xxxx normálně xxxxxxx xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " xx vztahuje x xxxxx, kterou může xxxx produkovat xxxxxxxxx. |
S2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX X PŘÍBUZNÉ XXXXX
Xxxxxxxxxxx látky x xxxxxx uvolňující faktory xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (XXX), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx faktoru (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx beta (XXXX), xxxxxxxxxxx /Xxxxxxxx/);
2. Xxxxxxxxxxxxxxxxxx (XX) x Iuteinizační hormon (XX) u mužů;
3. Insuliny;
4. Xxxxxxxxxxxxxx;
5. Xxxxxxx xxxxxx (XX), xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXXx), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (XXX-1), xxxxxxxxxx růstové xxxxxxx (XXX), růstový xxxxxx xxxxxxxx x krevních xxxxxxxx (PDGF) x xxxxxxxxxx-xxxxxxxxxxxx růstový xxxxxx (XXXX), stejně xxxx xxxxxxxxx xxxx růstové xxxxxxx xxxxxxxxxxx xxxxxxx xxxx degradaci xxxxxxxx xxxxx, xxxxx a xxxxxx, krevní xxxxxxxx, xxxxxxx energie, xxxxxxxxxxxxx xxxxxxxx nebo ovlivňující xxxx xxxxxxxxx vláken;
x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.
X3. XXXX2- AGONISTÉ
Xxxxxxx xxxx-2 xxxxxxxx (xxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx) xxxx xxxxxxxx xxxxx xxxxxxxxxxx (maximálně 1600 mikrogramů xx 24 xxxxx), xxxxxxxxxxx (xxxxxxxxx 36 mikrogramů xx 24 hodin) x xxxxxxxxxxx pokud xxxx podány v xxxxxxxx v souladu x xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx.
Přítomnost xxxxxxxxxxx x moči x xxxxxxxxxxx vyšší xxx 1000 ng/ml x xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx vyšší xxx 30 xx/xx nebude xxxxxxxxxx za zamýšlené xxxxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxxx xx xxxxxxxxx laboratorní xxxxx, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, xx abnormální výsledek xxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx inhalační xxxxx xxxxx xxx výše xxxxxxx xxxxxxx.
X4. XXXXXXXXX A METABOLICKÉ XXXXXXXXXX
Zakázané je xxxxxxxxxxx:
1. Inhibitory xxxxxxxx, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-oxo),exemestan, xxxxxxxxx, xxxxxxxx, testolacton, xxx xx x xxxxxxxx xxxxx na xx.
2. Xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, ale ne x xxxxxxxx pouze xx xx.
3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:
Cyklofenil, xxxxxxxxxxx, xxxxxxxx, ale xx x omezením xxxxx xx xx.
4. Xxxxx xxxxxxxxxxxx funkce xxxxxxxxxx xxxxxx inhibitorů xxxxxxxxxx, ale ne x xxxxxxxx xxxxx xx xx.
5. Xxxxxxxxxxx modulátory: Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Xxxxxxxxxx Proliferator Xxxxxxxxx Receptor δ (XXXXδ) xxxxxxxx/ (xxxx. GW 1516) x Agonisté proteinkinasové xxx xxxxxxxxxx AMP x xxxxxxxxxxx x XXXX xxxxx /PPARδ-AMP-activated xxxxxxx xxxxxx (AMPK) xxxx xxxxxxxx/ (xxxx. XXXXX)
S5. XXXXXXXXX X OSTATNÍ XXXXXXXXX XXXXX
Maskovací látky xxxx xxxxxxxx. Zahrnují:
Xxxxxxxxx, desmopressin, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx xxxxxx albuminu, dextranu, xxxxxxxxxxxxxxxxxx x mannitolu), xxxxxxxxxx a xxxxx xxxxx s xxxxxxxxx xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxx xxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx:
Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, indapamid, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, spironolakton, thiazidy (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx biologickými xxxxxx (xxxxx drospirenonu, xxxxxxxxx a xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, které nejsou xxxxxxxx).
Pro xxxxxxx (Xxx Xxxxxxx, xxxxxxxx Xxxx Soutěž) xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx prahovým limitem (xx. xxxxxxxxxx, salbutamol, xxxxxx, katin, xxxxxxx, xxxxxxxxxxxx a xxxxxxxxxxxxx) xx xxxxxxx s xxxxxxxxxx xxxx jinou xxxxxxxxx látkou xx xxxxxxxxxx xxxxxxx specifické Xxxxxxxxxxxx xxxxxxx na xxxx xxxxx xxxxx x xx, xxxxx xxx xxxx xxxxxxx xx diuretikum xxxx xxxxx xxxxxxxxx xxxxx.
XXXXXXXX XXXXXX
X1. XXXXXXXXX XXXXXXX XXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxx doping, xxxxxx použití xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxx a xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx.
2. Umělé xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx kyslíku, xxxxxxxxxx modifikované xxxxxxxxxxxxx xxxxxxxx (xxxx.xxxxxx náhražky xxxxxxxx xx xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx hemoglobiny), perfluorochemikálie x efaproxiral (RSR13), xxx xx x xxxxxxxx pouze na xx. Dodávání kyslíku xxxxxxxx není.
M2. XXXXXXXX A FYZIKÁLNÍ XXXXXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
1. Podvádění, xxxx pokus x xxxxxx, xx účelem xxxxxxx xxxxxxxxx a xxxxxxxx Xxxxxx xxxxxxxxxx xxx Dopingové kontrole xx xxxxxxxx. To xxxxxxxx xxxxxx x/xxxx xxxxxx (např. xxxxxxxxxx) xxxx, xxx xx x xxxxxxxx pouze xx ně.
2. Xxxxxxxxxx infuze a/nebo xxxxxxx xxxx xxx 50 xx za 6 xxxxx jsou xxxxxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx v xxxxxxx nemocničních xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxx.
3. Xxxxxxxx xxxxx, xxxxxxxxxx x xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxx krve do xxxxxxxxx systému xx xxxxxxxx.
M3. XXXXXX XXXXXX
X xxxxxx xxxxxxxxxx xx zvýšení xxxxxxxxxxx xxxxxx je xxxxxxxx xxxxxxxxxxx:
1. Xxxxxxxx xxxxxxxxxx kyselin xxxx jejich xxxxxxxx;
2. Použití xxxxxxxxxx xxxx xxxxxxxxx modifikovaných xxxxx;
XXXXX X XXXXXX XXXXXXXX XXX XXXXXXX |
Xxxxx xxxxxxxxx XX xx X5 a X1 xx X3 xxxxxxxxx xxxx xxxx Xxx Xxxxxxx xxxxxxxx x následující skupiny:
XXXXXXXX LÁTKY
X6. XXXXXXXXXXX
Xxxxxxx stimulancia (xxxxxx xxxx jejich xxxxxxxxxx optických xxxxxxx) xxxx xxxxxxxx, s xxxxxxxx derivátů xxxxxxxxx x případě xxxxxx xxxxxxxx použití a xxxxxxxxxxx xxxxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2012*.
Xxxxxxxxxxx xxxxxxxx:
(x) Nespecifická xxxxxxxxxxx:
Adrafinil, xxxxxxxxxx, xxxxxxxxxxx, amfetamin, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, benzylpiperazin, xxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, fenkamin, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-fenylpiracetam (xxxxxxxx), furfenorex, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, krotetamid, xxxxxxxxx, mefentermin, xxxxxxxxxxxx (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, norfenfluramin, x-xxxxxxxxxxxxxxx, prenylamin, xxxxxxxxx.
Xxxxxxxxxxxx, xxxxx není xxxxxxxx uvedeno x xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxxx stimulancia (xxxxxxxx):
Xxxxxxxxx**, xxxxx***, xxxxxxx****, xxxxxxxx, etilefrin, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, levmetamfetamin, meklofenoxát, xxxxxxxxxxxx****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), niketamid, norfenefrin, xxxxxxxxx, oxilofrin, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými účinky.
* Xxxxxxxxxxx xxxxx xxxxxxxx do Monitorovacího xxxxxxxx 2012 (bupropion, xxxxxxxxxx, fenylpropanolamin, kofein, xxxxxxx, xxxxxxxxx, xxxxxxxx) xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.
** Xxxxxxx xxxxxx xxxxxxxxxx (xxxx. nosní, xxxx xxxxxxxx) nebo xxxx xxxxxx xxxxxxxx s xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.
*** Katin xx xxxxxxxx pouze xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.
**** Efedrin x xxxxxxxxxxxxx jsou xxxxxxxx při xxxxxxxxxxx xxxxx než 10 xxxxxxxxxx v 1 xx moči.
***** Xxxxxxxxxxxxx je zakázán, xxxxx xxxx koncentrace x moči xx xxxxx xxx 150 xxxxxxxxxx xx xxxxxxxx
X7. NARKOTIKA
Xxxxxxxx xx xxxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), fentanyl x xxxx deriváty, xxxxxxxxxxx, xxxxxxx, morfin, xxxxxxxx, oxymorfon, xxxxxxxxxx, xxxxxxx.
X8. KANABINOIDY
Xxxxxxxx (xxxx. xxxxx, xxxxxx x marihuana) xxxx xxxxxxxxxx xxxxx9xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxxxxxxxxx (xxxx. "Spice" /xxxxxxxxxx XXX018, JWH073/ a XX-210) xxxx xxxxxxxx.
X9. GLUKOKORTIKOSTEROIDY
Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx orálně, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx aplikací jsou xxxxxxxx.
XXXXX XXXXXXXX X XXXXXXXX XXXXXXXX |
P1. XXXXXXX
Alkohol (etanol) xx zakázaný xxxxx Xxx Soutěži x xxxxxxxxxxxxx xxxxxxxx. Detekce xx xxxx xxxxxxxx xxxxxxxx xxxxxxxx a/nebo xxxxxxxx xxxx. Xxxxxxx xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) xx 0.10 x/x.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxx (WKF)
∙ Xxxxxxx sporty x xxxxxxxxxxxx(XXX)
∙ Lukostřelba (XXXX)
∙ Xxxxxxxxxxx xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XXX)
X2. XXXX-XXXXXXXXX
Xxxxx xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx sportech.
∙ Automobilový sport (XXX)
∙ Xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
∙ Xxxxx (XXX)
∙ Golf (XXX)
∙ Kuželky x xxxxxxx (XXX)
∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx (XXX)
∙ Xxxxxxxxxxx (FITA, XXX) (xxxxxxxx také Xxxx xxxxxx)
∙ Xxxxxxxx (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx a X-xxxxx,x xxxxxxxxx U-rampa x "big xxx"
∙ Xxxxxxxx x xxxxxxx sporty (XXXX)
∙ Střelba (XXXX, XXX) (zakázané xxxx Xxxx soutěž)
∙ Xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (UlM)
Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:
Xxxxxxxxxx, alprenolol, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, oxprenolol, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx ne s xxxxxxxx xxxxx na xx.
Xxxxxxxxx
Xxxxxx xxxxxxx č. 97/2012 Xx. m. x. xxxxx xxxxxxxxx xxxx 25.12.2012.
Xxxxxx předpis x. 97/2012 Xx. x. x. xxx zrušen xxxxxxx xxxxxxxxx č. 98/2013 Sb. m. s. x účinností xx 20.12.2013.
Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx právních předpisů x odkazech xxxx xxxxxxxxxxxxx, xxxxx xx xxxx netýká xxxxxxxxx xxxxx shora uvedeného xxxxxxxx xxxxxxxx.